Albert Labs International (XCNQ:ABRT) Debt-to-Equity : -0.02 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International Debt-to-Equity?

Albert Labs International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$0.00 Mil. Albert Labs International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$0.01 Mil. Albert Labs International's Total Stockholders Equity for the quarter that ended in Sep. 2023 was C$-0.44 Mil. Albert Labs International's debt to equity for the quarter that ended in Sep. 2023 was -0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Albert Labs International's Debt-to-Equity or its related term are showing as below:

XCNQ:ABRT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: -0.02 Max: -0.02
Current: -0.02

During the past 2 years, the highest Debt-to-Equity Ratio of Albert Labs International was -0.02. The lowest was -0.02. And the median was -0.02.

XCNQ:ABRT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:ABRT: -0.02

Albert Labs International Debt-to-Equity Historical Data

The historical data trend for Albert Labs International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International Debt-to-Equity Chart

Albert Labs International Annual Data

Trend

Dec21

Dec22

Debt-to-Equity

Albert Labs International Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial					-	-	-	-	-0.02

Competitive Comparison of Albert Labs International's Debt-to-Equity

For the Biotechnology subindustry, Albert Labs International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albert Labs International's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albert Labs International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Albert Labs International's Debt-to-Equity falls into.

Albert Labs International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Albert Labs International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-0.365
	=	0.00

Albert Labs International's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.01)	/	-0.443
	=	-0.02

Albert Labs International (XCNQ:ABRT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Albert Labs International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Albert Labs International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Albert Labs International (XCNQ:ABRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6

Website

https://www.albertlabs.com

Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines